Details for Patent: 8,475,839
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,475,839 protect, and when does it expire?
Patent 8,475,839 protects EXFORGE HCT and is included in one NDA.
Protection for EXFORGE HCT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-five patent family members in twenty-two countries.
Summary for Patent: 8,475,839
Title: | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Abstract: | Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made. |
Inventor(s): | Cao; Yu (Parsippany, NJ), Joshi; Yatindra (Princeton, NJ), Li; Ping (Basking Ridge, NJ), Pudipeddi; Madhusudhan (Mumbai, IN), Royce; Alan E (Saylorsburg, PA), Wagner; Robert F (Hillsborough, NJ), Zhu; Jiahao (Whippany, NJ) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 13/342,533 |
Patent Claim Types: see list of patent claims | Compound; Dosage form; Composition; |
Drugs Protected by US Patent 8,475,839
International Family Members for US Patent 8,475,839
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 061627 | See Plans and Pricing | |||
Australia | 2007265138 | See Plans and Pricing | |||
Brazil | PI0713785 | See Plans and Pricing | |||
Canada | 2654986 | See Plans and Pricing | |||
Chile | 2007001870 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |